Thiopurine monotherapy effective in ulcerative colitis, but less so in Crohn’s disease

  • Stournaras E & al.
  • Gut
  • 1 Oct 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Thiopurine monotherapy is an effective long-term treatment for ulcerative colitis (UC), but significantly less effective in Crohn’s disease (CD), particularly where there is perianal involvement.

Why this matters

  • Given recent substantial reductions in the cost of biosimilars and the evidence presented regarding the relative lack of durable effectiveness of thiopurine monotherapy in CD, there is perhaps a need to re-evaluate treatment strategy of using thiopurines as maintenance for patients with CD.

Study design

  • A retrospective analysis of long-term outcomes of thiopurine monotherapy for 11,928 patients with inflammatory bowel disease (IBD) (UC, n=4968; CD, n=6960) in the UK IBD BioResource (68,132 patient-years of exposure).
  • Funding: None disclosed.

Key results

  • Thiopurine monotherapy was effective for the duration of treatment in 2617/4968 (52.7%) patients with UC vs 2378/6960 (34.2%) patients with CD (P<.0001>
  • Multivariable logistic regression analysis demonstrated that thiopurine monotherapy was less effective in CD than UC (OR, 0.47; 95% CI, 0.43-0.51; P<.0001 adjusting for variables including treatment era.>
  • For CD, treatment initiation ≤1 year after IBD diagnosis (OR, 0.69; 95% CI, 0.60-0.78; P<.0001 and perianal disease ci p correlated lower thiopurine effectiveness.>
  • For UC, proctitis was associated with higher effectiveness (OR,1.56 vs extensive disease; 95% CI, 1.23-1.98; P=.0002).
  • On Kaplan-Meier analysis, median duration on thiopurines in those in whom they were effective was 16 years for CD and 17 years for UC.
  • Inability to tolerate thiopurines was associated with an increased risk of surgery in UC (HR, 2.44; 95% CI, 1.71-3.50; P<.0001 with a more modest effect in cd ci p=".0015).</li">

Limitations

  • Retrospective design.